Microlife is an international medical-device manufacturer recognised for its blood-pressure monitors, digital thermometers, respiratory-care devices and other home-health diagnostic equipment. While the brand traces its origins to Taiwan in 1981, its corporate entity, Microlife AG, is headquartered in Widnau, Switzerland. The company positions itself as a leading manufacturer of thermometers and a key player in blood-pressure monitoring and home diagnostics.

The Swiss legal entity is registered as Microlife AG in Widnau.1

Microlife operates as a medical technology and diagnostic-equipment brand, distinct from general consumer-electronics companies. Its products are engineered to measure or monitor health parameters, specifically targeting conditions that can be managed outside hospital settings. The company’s core business areas include:

• Blood-pressure monitors
• Digital and infrared thermometers
• Nebulizers and respiratory-care equipment
• Pulse oximeters
• Peak-flow meters
• Blood-glucose monitoring systems
• Flexible heating products
• Connected health devices and applications

The equipment is designed for both home monitoring and institutional healthcare use. The company’s stated goal is to provide individuals with information that enables them to take greater responsibility for their health.2

Foundation (1981)

The history of Microlife begins in 1981 with the founding of Micro Idea Instruments Co. Ltd. in Taiwan. Initially operating from a Taipei electronics research laboratory, one of its earliest innovations was a digital clinical/fertility thermometer, developed as an alternative to traditional analogue models. This early focus on digitising medical measurement established the foundation for the company’s future operations.

Early Development (1980s)

During the 1980s, the company expanded its work into electronic thermometers and blood-pressure measurement. In 1982, it received a gold medal for a thermometer innovation. By the mid-1980s, it had introduced one of the world’s early pen-type thermometer systems, including FDA approval.3 This period defined the company’s basic strategy: combining electronics, medical measurement, and consumer usability.

Formation of Microlife Group (1993)

The Microlife Group was formally established in 1993. Throughout the 1990s, the company began expanding internationally and developing more sophisticated electronic diagnostic products.

Digital Blood-Pressure Monitoring (1995)

A significant milestone occurred in 1995 with the launch of the first digital blood-pressure monitoring system, the 3BT0A. The company also obtained ISO 9001 and EN 46001-related certifications at its headquarters and factory, facilitating expansion into regulated medical-device markets.

Swiss Headquarters (1996)

In 1996, Microlife AG Switzerland was established. Consequently, while the historical origins are Taiwanese, the brand is frequently described commercially as a Swiss medical-device brand due to its corporate headquarters location.

International Expansion (1997–2002)

Operations were subsequently established in the United States, Britain and France. In 2001, the group conducted its first IPO. In 2002, Microlife introduced its MAM — Microlife Average Mode technology for blood-pressure measurement.

MAM Technology

One of Microlife’s signature technologies is MAM (Microlife Average Mode). Instead of relying on a single reading, MAM automatically performs three sequential measurements to produce a more representative result. This process helps reduce the influence of unusually high or low individual readings caused by natural blood pressure fluctuations. Introduced commercially in 2002, MAM remains a feature in current blood-pressure products.

AFIB Sensing

Another major component of the technological identity is AFIBsens™, which detects possible atrial fibrillation (AF) during blood-pressure measurement. Atrial fibrillation is an irregular heart rhythm associated with increased stroke risk. The system analyses pulse irregularity patterns; if a suggestive pattern is detected, the device displays an AFIB indication. The company states that AFIBsens is not a diagnosis and requires follow-up medical evaluation.5 Clinical development involving AF detection dates to 2009, with the technology integrated into the portfolio around 2012.6

Consumer Healthcare

Products such as BP B-series monitors, thermometers, pulse oximeters, nebulizers and glucose monitors are designed primarily for home use.

Professional Healthcare (WatchBP)

The WatchBP family targets healthcare professionals and clinical environments. These systems support office blood-pressure measurement, ambulatory monitoring, atrial-fibrillation screening, ankle-brachial-index measurement and specialized clinical applications. The range has accumulated validation studies involving hypertension, pregnancy, diabetes and paediatric populations.

Thermometers

Thermometers remain a core category. The range includes traditional digital, flexible, antimicrobial, infrared ear, non-contact forehead and Bluetooth-enabled models. The company describes itself as a leading manufacturer of thermometers.

Respiratory Care

This category includes compressor, portable, mesh and children’s nebulizers, as well as peak-flow meters and pulse oximeters. These devices are relevant for monitoring asthma and other chronic respiratory diseases.

Blood-Glucose Monitoring

Expanding into diabetes diagnostics, the portfolio includes systems such as GlucoTeq, DiaRite and Gluco-A+. A new range of blood-glucose monitors was launched in 2020.

Connected Health

The Microlife Connected Health+ ecosystem allows compatible devices to transfer health measurements—such as blood pressure, body temperature, body composition and respiratory data—to smartphone applications. Current examples include Bluetooth-enabled blood-pressure monitors like the BP B4 BT, which combines connectivity with MAM technology.7

Microlife operates as an international company rather than being focused solely on Switzerland or Taiwan. Its structure involves:

• Global offices in the United States, Switzerland and Taiwan
• Additional branch offices
• Multiple manufacturing sites
• Distribution in approximately 90 countries

The company’s identity combines Taiwanese electronics engineering with Swiss corporate and medical-device infrastructure. A simplified representation of this evolution is:

Taiwanese origins → Electronics expertise → International expansion → Swiss headquarters → Global medical-device company

Therefore, describing Microlife simply as a “Swiss brand” is incomplete historically; it is accurately described as a global medical-device company founded in Taiwan with Swiss headquarters.

A central aspect of the brand positioning is clinical validation. The company maintains a database of studies covering adult blood-pressure measurement, atrial fibrillation, pregnancy, pre-eclampsia, diabetes, paediatric measurement, cuff accuracy, ambulatory monitoring and ankle-brachial index. Independent validation against recognized protocols is a key consideration for evaluating medical blood-pressure monitors.4

Microlife has received various design and innovation recognitions, including:

• Red Dot Award for the BP A6 PC
• Red Dot Award for the NC 200 thermometer
• Red Dot Product Design Award 2021 for the BP A7 Touch BT
• German Design Council recognitions
• Frost & Sullivan Product Differentiation Innovation Award

These awards highlight competition based on product design and user experience alongside medical functionality.

The corporate philosophy centres on empowering people to monitor their own health. The stated vision uses medical technology to provide individuals with the information needed to understand and improve their health. Key emphasis areas include:

1. Quality
2. Precision
3. Reliability
4. Medical technology
5. Ease of use
6. Home-based health monitoring

The slogan reflects this approach: “Empower people for a healthy today and a better tomorrow.”2

Microlife is moving toward a model where the medical device is part of a broader healthcare ecosystem. The evolution follows a trajectory from digital measurement (1980s) to electronic home diagnostics (1990s), clinically validated blood-pressure technology (2000s), AFIB and professional monitoring (2010s), and finally to glucose monitoring combined with Bluetooth and connected health (2020s). The current direction focuses on integrated digital home-health monitoring via platforms like Connected Health+.7

1. History – Microlife AG
2. Empower people for a healthy today and a better tomorrow – Microlife AG
3. Our History – Microlife
4. Giới Thiệu Microlife
5. MICROLIFE CORPORATION
6. Microlife AG in Widnau – Auskünfte
7. MICROLIFE HEALTH MANAGEMENT LIMITED persons with significant control – Find and update company information – GOV.UK